MeReC Extra issue no. 37 has published an article on
Anticholinergics in COPD - new data on cardiovascular safety
ABSTRACT: A large meta-analysis of 17 randomised controlled trials suggests that inhaled anticholinergic drugs increase the risk of CV events in people with COPD compared with placebo or active comparators.
However the precise magnitude of this increased risk is uncertain. In addition results from the UPLIFT trial provide limited reassurance about the CV risk of tiotropium.
References and full text copy available from the library
No comments:
Post a Comment